ClinicalTrials.gg
CompletedNCT06094725Updated Oct 23, 2023

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

A Phase 1 interventional study of Relacorilant in Hepatic Impairment, sponsored by Corcept Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2020, 5 years 11 months ago, and no results have been posted to the registry.
  • Registered 3 years 9 months after the study started (first participant enrolled Jan 2020, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The primary objective of this multiple-dose, adaptive design study is to evaluate the effect of hepatic impairment on the pharmacokinetics (PK) of relacorilant relative to healthy matched control male and female subjects (Part 1).

Read the detailed description

If an obvious effect of moderate hepatic impairment on exposure to relacorilant is observed in Part 1, optional Part 2 of the study will be conducted. In Part 2, the effect of mild hepatic impairment on the PK of relacorilant will be evaluated, using control data from the same healthy control subjects who were matched to the subjects in Part 1.

Secondary objectives of the study are 1) evaluation of the effect of hepatic impairment on the PK of relacorilant metabolites, and 2) evaluation of safety and tolerability of relacorilant on healthy subjects and those with hepatic impairment.

02

Conditions studied

  • Hepatic Impairment
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand the purpose and risks of the study and is willing and able to adhere to scheduled visits, treatment plans, laboratory tests, and other study evaluations and procedures
  • Provide written before any study-specific procedure is performed
  • Male or a nonpregnant, nonlactating female judged to be in good health, except for allowance of health conditions consistent with hepatic impairment
  • (BMI) between 18 and 32 kg/m\^2, inclusive, and a body weight more than 50 kg (110 pounds)
  • Estimated (eGFR) ≥80 mL/minute/1.73 m\^2
  • Suitable veins for multiple venipuncture/cannulation
  • Agrees to limit smoking or use of tobacco or nicotine-containing products to less than 5 cigarettes or uses per day
  • Willing to comply with study restrictions as described in the protocol
  • Female subject is of either nonchildbearing potential (ie, or permanently sterilized) or uses highly effective with low user-dependency, as described in the protocol.

Subjects with normal hepatic function must also satisfy the following inclusion criteria:

  • Clinical laboratory results within the reference range at Screening and Day -1, unless considered not by the Principal Investigator
  • Negative screening results for surface antigen, virus antibody, and antibodies.

Subjects with moderate or mild hepatic impairment must also satisfy the following inclusion criteria:

  • Documented parenchymal hepatic disease
  • Liver dysfunction of moderate ( Class B [score of 7 to 9]; Part 1) or mild (Child-Pugh Class A [score of 5 to 6]; Part 2) severity
  • Stable hepatic impairment defined as no clinically significant change in disease status within the last 30 days
  • On a stable dose of medication and/or treatment regimen at least 2 weeks before study drug dosing
  • If a subject has nonhepatic abnormal clinical laboratory results, these results are considered not clinically relevant by the Principal Investigator (or designee) and the medical monitor.

Exclusion criteria

Exclusion Criteria:

  • An employee or immediate family member of the Clinical Research Unit (CRU) or the Sponsor
  • Has been previously enrolled in any study of relacorilant
  • Has multiple drug allergies or is allergic to any of the components of relacorilant
  • Has a condition that could be aggravated by excessive receptor antagonism. Subjects with inactive seasonal hay fever or childhood asthma may be included.
  • Has a history of malabsorption syndrome or previous gastrointestinal surgery that could affect drug absorption or metabolism
  • Has Gilberts syndrome
  • Has current or previous (within a 1-year period) alcohol or substance abuse and/or dependence
  • Has evidence of acute viral hepatitis in the 3 calendar months before the first dose of study drug
  • In the 2 calendar months before the first dose of study drug, subject has: donated/lost blood or plasma in excess of 400 mL, or received an drug
  • Has a positive result for alcohol or drugs of abuse at Screening or upon admission to the CRU
  • Has clinically relevant abnormal vital signs, physical examination, laboratory tests, or 12-lead findings at Screening and/or before the first dose of study drug, other than those associated with chronic hepatic impairment
  • Has taken any prohibited prior medication, as described in the protocol
  • Has any other condition that might increase the risk to the individual or decrease the chance of obtaining satisfactory data, as assessed by the Principal Investigator.

Additional exclusion criteria for subjects with moderate or mild hepatic impairment:

  • Has hepatic encephalopathy of Grade 2 that has not been controlled with medication for the previous 3 calendar months before Screening or of Grade 3 or higher within the previous 3 calendar months before Screening, regardless of use of medication for the treatment of hepatic encephalopathy
  • Has a history of liver transplantation, hepatocellular carcinoma, portosystemic shunt, or acute liver disease (eg, caused by infection or drug toxicity).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    No Hepatic Impairment

    Subjects with no hepatic impairment will receive relacorilant 300 mg once daily on Days 1 through 10.

    Drug: Relacorilant

  • Experimental
    Moderate Hepatic Impairment

    Subjects with moderate hepatic impairment (Child-Pugh Class B) will receive relacorilant 300 mg once daily on Days 1 through 10.

    Drug: Relacorilant

  • Experimental
    Mild Hepatic Impairment

    Subjects with mild hepatic impairment (Child-Pugh Class A) will receive relacorilant 300 mg once daily on Days 1 through 10.

    Drug: Relacorilant

Interventions

  • Relacorilant 300 mg (3 X 100 mg softgel capsules) for oral administration

    Also known as: CORT125134

06

What researchers measure

Primary outcomes

  1. Maximum concentration of plasma relacorilant during the dosing interval (Cmax)

    Time frame: Predose and at serial time points up to 24 hours after dosing on Day 10

  2. Area under the concentration-time curve of plasma relacorilant from time zero to the end of the dosing interval (24 hours) (AUCt)

    Time frame: Predose and at serial time points up to 24 hours after dosing on Day 10

Secondary outcomes

  1. Cmax of relacorilant plasma metabolites

    Time frame: Predose and at serial time points up to 24 hours after dosing on Day 10

  2. AUCt of relacorilant plasma metabolites

    Time frame: Predose and at serial time points up to 24 hours after dosing on Day 10

  3. Number of subjects with one or more treatment-emergent adverse events

    Time frame: Up to Day 20

  4. Number of subjects with one or more treatment-emergent adverse events by severity

    Time frame: Up to Day 20

07

Study locations

2 sites
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Dec 2020, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 23, 2023
StartActual
Jan 6, 2020
Primary completionActual
Dec 14, 2020
CompletionActual
Dec 14, 2020
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06094725
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Jan 6, 2020
Primary completion
Dec 14, 2020
Completion
Dec 14, 2020
Last update
Oct 23, 2023

Study contacts

Joseph Custodio
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relacorilant

Start the discussion